Abstract
Collaborative efforts by pediatric and adult gastroenterologists, allergists, dieticians, and pathologists have brought about marked progress in the recognition, understanding, and management of eosinophilic esophagitis (EoE) over the past two decades. Once an esoteric diagnosis, EoE is now increasingly identified as a major cause of morbidity, afflicting both children and adults. The detection of mucosal eosinophils has evolved from a diagnostic feature of acid reflux to a biomarker of food sensitization of the esophagus. Translational studies and murine models have elucidated Th-2 immune pathways in EoE, inspiring the development of targeted biologic therapeutics. At the same time, validation of patient-reported outcomes and endoscopic end points has facilitated the implementation of clinical trials of novel therapeutics. Ongoing investigations have elucidated the importance of "looking beneath the surface" of the epithelium, focusing greater attention on the impact of esophageal remodeling in the clinical consequences of EoE. Elimination diets continue to gain popularity as an intriguing, highly effective, and non-pharmacologic therapy that lends credence to the concept that EoE is a food-driven, immunologic disorder.
Original language | English (US) |
---|---|
Pages (from-to) | 770-776 |
Number of pages | 7 |
Journal | American Journal of Gastroenterology |
Volume | 111 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2016 |
Funding
Dr Hirano has received grant support from the NIH Consortium of Eosinophilic Gastrointestinal Disease Researchers (NIH U54AI117804), which is part of the Rare Disease Clinical Research Network, an initiative of the Offi ce of Rare Disease Research funded through a collaboration between NIAID, NIDDK, and NCATS, and an American Society of Gastrointestinal Endo scopy Research Award.
ASJC Scopus subject areas
- Gastroenterology
- Hepatology